{"analyses":[{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"99.1","ciUpperLimit":"1.28","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.76","paramType":"Hazard Ratio (HR)","paramValue":"0.97","statisticalMethod":"Regression, Cox"},{"ciLowerLimit":"0.52","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.79","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.64","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.7","upperLimit":"71.49","value":"60.42"},{"groupId":"OG001","lowerLimit":"48.53","upperLimit":"82.33","value":"66.92"},{"groupId":"OG002","lowerLimit":"37.88","upperLimit":"56.94","value":"46.92"},{"groupId":"OG003","lowerLimit":"67.19","upperLimit":"116.63","value":"82.33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"376"},{"groupId":"OG002","value":"377"},{"groupId":"OG003","value":"374"}],"units":"Participants"}],"description":"The duration of survival is the time interval between randomization and the date of death due to any cause. Patients not reported dead or lost to follow up will be censored at the date of the last follow up examination.","dispersionType":"95% Confidence Interval","groups":[{"description":"Including 2 randomized arms: Arm RT alone and Arm RT followed by adjuvant TMZ","id":"OG000","title":"Absence of Concomitant Temozolomide (TMZ)"},{"description":"Including 2 randomized arms: Arm TMZ/RT and Arm TMZ/RT followed by adjuvant TMZ","id":"OG001","title":"Presence of Concomitant Temozolomide (TMZ)"},{"description":"Including two randomized arms: Arm RT alone and Arm TMZ/RT","id":"OG002","title":"Absence of Adjuvant Temozolomide (TMZ)"},{"description":"Including to 2 randomized arms: Arm RT followed by adjuvant TMZ and Arm TMZ/RT followed by adjuvant TMZ","id":"OG003","title":"Presence of Adjuvant Temozolomide (TMZ)"}],"paramType":"MEDIAN","populationDescription":"This trial studied 2 questions 1) effect of concomitant Temozolomide (TMZ) 2) effect of adjuvant TMZ. The 4 randomized arms were combined. Absence of concomitant TMZ including Arm Radiotherapy (RT) alone \\& Arm RT followed by adjuvant TMZ. Presence of concomitant TMZ including Arm TMZ/RT \\& Arm TMZ/RT followed by adjuvant TMZ. Absence of adjuvant TMZ including Arm RT alone \\& Arm TMZ/RT. Presence of adjuvant TMZ including Arm RT followed by adjuvant TMZ \\& Arm TMZ/RT followed by adjuvant TMZ","reportingStatus":"POSTED","timeFrame":"from date from enrollment till the date of death (time till death is up to 10.9 years after patient enrollment in the study)","title":"Overall Survival as Measured From the Day of Randomization","type":"PRIMARY","unitOfMeasure":"Months"}